Date: 2014-01-10
Type of information: R&D agreement
Compound: miRNAs
Company: InteRNA Technologies (The Netherlands) UCB (Belgium) University of Bonn (Germany)
Therapeutic area: Neurodegenerative diseases
Type agreement: R&D
collaboration
Action mechanism:
Disease: neurodegenerative diseases
Details: * On January 10, 2014, InteRNA Technologies, a Dutch biopharma company engaged in the development of microRNA (miRNA)-based therapeutics, and the Neuroallianz Consortium, an academic industry partnership with UCB and the Rheinische Friedrich-Wilhelms-University of Bonn (Germany) as 2 of the total 10 partners have entered into an agreement where InteRNA will support the investigation of miRNAs in neurodegenerative diseases. Under the agreement, InteRNA, working closely with Jeroen Pasterkamp, Professor of Translational Neuroscience at UMC Utrecht, will apply its platform for multi-parametric, high-throughput functional screening assays to identify and validate the biological role of individual miRNAs and novel therapeutic targets for neurodegenerative disease.
This collaboration forms an integral part of the Neuroallianz project miRNAs in Neurodegenerative Diseases partnered by the University of Bonn and UCB and funded by the Federal Ministry for Education and Research (BMBF) in Germany.
Financial terms:
Latest news:
